Cardiac Resynchronization Therapy for the Atrium (CRT-A)

Rhythm360: Restoring Rhythm and Atrial Function

The Unmet Need: AF-HFpEF Is an Atrial Disease Without a Solution

Heart failure with preserved ejection fraction (HFpEF) now accounts for nearly half of all heart-failure cases—yet no approved device therapy exists.

Atrial dysfunction is the hidden driver of HFpEF decline, fueling atrial fibrillation (AF), hospitalizations, and mortality.

Current therapies fall short:

  • Medications cannot restore atrial mechanics.

  • Ablation often leaves the atria scarred and mechanically impaired

Why the Atrium — and Why Now

AF-HFpEF is fundamentally a disease of atrial dysfunction.
Loss of coordinated atrial contraction elevates left-atrial pressure, impairs ventricular filling, and worsens exercise tolerance and survival.

Addressing atrial function early may prevent irreversible remodeling—preserving both rhythm and cardiac efficiency.

Clinical evidence is clear:

  • Atrial dysfunction doubles hospitalization and mortality risk in HFpEF patients.【Reddy et al., JACC Heart Fail, 2023】

  • Reduced LA strain predicts poor outcomes and persistent congestion despite sinus rhythm restoration.【Freed et al., Eur Heart J, 2022】

  • Post-ablation LA strain abnormalities persist, driving AF recurrence and incomplete hemodynamic recovery.【Park et al., Heart Rhythm, 2021】

  • No approved therapy exists to restore atrial synchrony or function in AF-HFpEF.

Rhythm360™: Intelligent, Multi-Mode CRT-A

Rhythm360 is an investigational, implantable system designed to restore and maintain atrial function through non-destructive, closed-loop electrical therapy.

Programmable modes addressing the full spectrum of atrial rhythm disorders:

  1. Prevention – Detects and suppresses AF triggers.

  2. Sinus Rhythm Restoration – Imperceptibly AF termination without ablation or shocks.

  3. BBp (Bachmann’s Bundle pacing) – Re-synchronizes atrial contraction and improves AV coordination.

Together, these adaptive modes deliver continuous, intelligent Cardiac Resynchronization Therapy for the Atrium (CRT-A) — supporting sinus rhythm, preserving atrial transport, and potentially altering the trajectory of AF-HFpEF.

  • Exciting News from MaxWell Biomedical!

    Maxwell Biomedical is expanding its ongoing clinical study to further validate the groundbreaking Spatial Resynchronization Therapy (SRT) for patients with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF).
    SRT is designed to imperceptibly terminate AF and restore atrial function and atrial synchrony —a non-destructive, next-generation approach that sets it apart from conventional ablation therapies. With this expansion, we aim to accelerate clinical insights, broaden patient access, and drive a paradigm shift in AF treatment for the AF-HFpEF population.

    Why It Matters:
    ·        Better Outcomes – SRT enhances atrial heart function while preventing AF, addressing a critical unmet need.
    ·        Expanded Study Scope – More patients, more data, stronger clinical validation.
    ·        Innovative Non-Destructive Approach – Unlike ablation, SRT does not destroy cardiac tissue but restores atrial conduction.

    As we take this next step, we’re grateful for our investors, clinical partners, and dedicated team members working to bring a new era of AF treatment to patients worldwide.

    Stay tuned for more updates!
    March 13, 2025

Cardiac Resynchronization Therapy for the Atrium (CRT-A

First Device Approach That Overcomes Past Limitations

Maximum Wellness

[ mak-suh-muhm ] [ wel-nis ]

Decades of AF Treatment Have Focused Soley on Tissue Destruction

Medicine Evolves: 🟥 Cox-Maze Surgery (1980s) →🟧 Catheter Ablation (1990s–Present) →🟩 Non-destructive (Future)